Prophylaxis for adults with haemophilia: Towards a personalised approach?

Blood Transfusion

Volumn 10, Issue 2, 2012, Pages 123-124

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a Hospital of Mantua   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLOOD TRANSFUSION; CLINICAL TRIAL (TOPIC); EDITORIAL; HEMARTHROSIS; HEMOPHILIA; HUMAN; NORTH AMERICA; PATIENT COMPLIANCE; PHENOTYPE; PROPHYLAXIS; SWEDEN;

ADULT; BLOOD COAGULATION FACTORS; HEMOPHILIA A; HUMANS; INDIVIDUALIZED MEDICINE; QUALITY OF LIFE;

EID: 84860499640     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0182-11     Document Type: Editorial

References (16)

1. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with hemophilia. Thromb Haemost 2009; 101: 674-81.
2. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16 (Suppl. 5): 181-8.
3. Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009; 23: 267-74.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44. (Pubitemid 47236278)
5. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study). J Thromb Haemost 2011; 9: 700-10.
6. Valentino LA. Controversies regarding the prophylactic management of adults with severe haemophilia A. Haemophilia 2009; 15 (Suppl. 2): 5-18.
7. Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9. (Pubitemid 24323199)
8. Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
9. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
10. Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 2012; 10: 169-73.
11. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
12. Østergaard H, Bjelke JR, Hansen L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
13. Richards M, Altisent C, Batorova A, et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007; 13: 473-9. (Pubitemid 47337985)
14. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21.
15. van Dijk K, Fischer K, van der Bom JG, et al. Can longterm prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12. (Pubitemid 40979141)
16. Tagliaferri A. Awaiting evidence-based recommendations on prophylaxis in adult patients. Haemophilia 2010; 16: 955-6.